Form 4 ABBOTT LABORATORIES For: Feb 28 Filed by: CAPEK JOHN M

Go back to Form 4 ABBOTT LABORATORIES For: Feb 28 Filed by: CAPEK JOHN M

Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), 'a preferential tiering for Libre could position it better for share gains in the larger T2 market'

March 6, 2023 10:19 AM EST

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $114.00 price target on Abbott Labs (NYSE: ABT).

The analyst comments "Market opportunity / implications: The T1 market is smalland we would expect ABT to get some incremental share in the T1 market going... More